China is the most populated country and an emerging economy. China prostate cancer market is forecast to grow at a CAGR of around 8.5% during the forecast period. The incidence of prostate cancer is less in the country as compared to western economies. As per the World Health Organization, the estimated new cases of prostate cancer in 2018 were 99,000 and 5-year prevalence is around 222,000. China government is taking positive steps to improve healthcare infrastructure, driving the prostate cancer market. The government is also increasing access to healthcare by broadening the reach of its health insurance schemes and spending on training hospital staff. In addition, it is involving the private sector by inviting them to build private hospitals or collaborating on innovation.

China prostate cancer diagnostic and therapeutics market is segmented on the basis of diagnostic techniques and therapeutics. By diagnostic technique the market is further is segmented into prostate-specific antigen test, digital rectal examination, prostate biopsy, imaging techniques. Imaging techniques segment is expected to have a significant growth rate in the country during the forecast period. By therapeutics, the market is further divided into hormonal therapy, chemotherapy, immunotherapy, radiation therapy, targeted therapy, surgery. Radiation therapy is the main treatment for localized prostate cancer, and a comprehensive therapy based on androgen deprivation therapy is the treatment for advanced disease. 

The companies which are contributing significantly in the market include Pfizer Inc., The Xian Janssen Pharmaceutical Ltd., Abbott Laboratories, AbbVie Products, LLC, Amgen Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Co., Ferring Pharmaceuticals Inc., GlaxoSmithKline PLC, Johnson & Johnson, Siemens Healthcare AG and others. The market players are considerably contributing to the market growth by the adoption of various growth strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market. For instance, in November 2019, the Xian Janssen Pharmaceutical Ltd. announced to launch ERLEADA (apalutamide), after the approval from China National Medical Products Administration (NMPA) in September 2019. Moreover, in the same month, Pfizer, Inc. announced the approval of Xtandi for men with metastatic castration-resistant prostate cancer (CRPC) and also who had disease progression despite androgen deprivation therapy (ADT). 

Research Methodology

The market study is incorporated by extensive primary and secondary research conducted by the research team.  Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. In the report, the analysis of the country is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts to brings authenticity to the reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report is intended for drug manufacturing companies, medical device manufacturing companies, contract manufacturers, government organizations, and venture capitalists for the comprehensive market analysis. The report provides an in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. China Prostate Cancer Market Research and Analysis by Diagnostic Technique
2. China Prostate Cancer Market Research and Analysis by Therapy

The Report Covers

• Comprehensive research methodology of China Prostate Cancer Market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting China Prostate Cancer Market.
• Insights about market determinants which are stimulating China Prostate Cancer Market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.